Skip to main
TNDM

TNDM Stock Forecast & Price Target

TNDM Analyst Ratings

Based on 19 analyst ratings
Buy
Strong Buy 21%
Buy 32%
Hold 47%
Sell 0%
Strong Sell 0%

Bulls say

Tandem Diabetes Care is expected to see revenue growth in the next few years with their new product launch and transition to selling through pharmacies. This may initially decrease revenue but lead to higher profits in the long term, while moderate growth in new patients and potential for increased profitability through cost management make this company attractive. There are potential risks, such as competition and difficulty accessing the pharmacy channel, but overall, the company's positive outlook is reflected in analyst assessments.

Bears say

Tandem Diabetes Care is facing multiple challenges in the highly competitive diabetes device market. Its dependence on sales in the US, which contribute to a significant portion of its revenue, exposes the company to political and healthcare policy risks. The lower profitability margins and execution risks for its transition to the pharmacy channel also justify a discount in its current valuation. Despite potential growth opportunities from its product portfolio, there is limited confidence in Tandem's ability to execute and drive significant profit growth in the near future, resulting in a negative outlook on its stock.

TNDM has been analyzed by 19 analysts, with a consensus rating of Buy. 21% of analysts recommend a Strong Buy, 32% recommend Buy, 47% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Tandem Diabetes Care and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Tandem Diabetes Care (TNDM) Forecast

Analysts have given TNDM a Buy based on their latest research and market trends.

According to 19 analysts, TNDM has a Buy consensus rating as of Aug 3, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $27.82, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $27.82, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Tandem Diabetes Care (TNDM)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.